Abstracts tagged "mesenchymal stem cells and therapy"

Abstract Number: 346 • 2014 ACR/ARHP Annual Meeting
Treatment of Collagen Induced Artritis with Human Embrionic Stem Cell-Derived Multipotent Mesenchymal Stromal Cells (hESC-MSC)
Gabriel Criado¹, María J. Pérez-Lorenzo¹, María Galindo², Jose L. Pablos², Pablo Menéndez³ and Elena Gonzalo-Gil⁴, ¹Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Josep Carreras Leukemia Research Insitute, Barcelona, Spain, ⁴Grupo de Investigación en Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain
Background/Purpose Inhibition of TGFβ signaling in human Embryonic Stem Cells (hESC) generates mesenchymal stromal cells (hESC-MSC) with osteogenic, adipogenic and chondrogenic potential. These cells have…
Abstract Number: 2218 • 2013 ACR/ARHP Annual Meeting
Gingival Stem Cells Suppress Osteoclast Formation and Bone Erosion In CIA Through CD39 Signal
Song Guo Zheng¹, Jian Gu², Maogeng Chen¹ and Yi Shen³, ¹Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, ²Medcine, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Medicine, Shanghai East Hospital at Tongji University, Shanghai, China
Background/Purpose: We recently have reported that human-derived gingival mesenchymal stem cells (GMSC) have strong capacity to suppress immune responses and T cell-mediated collagen-induced arthritis, however,…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.